Cancer Care

Bradley Pharmaceuticals, Inc. (NYSE: BDY) is encouraging everyone to visit their dermatologist for skin cancer screening as the summer season begins. Bradley’s Doak Dermatologics subsidiary, in partnership with The Skin Cancer Foundation, established The Skin Cancer Screening Tour last year and has been providing complimentary screenings for the general public throughout the country. Almost 7,000 individuals were screened since the Tour started in March 2006.

The Tour stops at cities throughout the U.S. where local, board-certified dermatologists perform free skin cancer evaluations in a 38-foot Mobile Diagnosis Vehicle (MDv) that was designed and built by Doak Dermatologics. The Tour actively promotes skin cancer awareness and reminds the general public about the importance of visiting their dermatologist for early detection and treatment of skin cancers. Skin cancer is often curable if diagnosed and treated early enough.

Since last year, the Tour visited 47 cities and identified more than 2,000 individuals as requiring further medical attention for a precancerous or cancerous condition. Over 1,400 individuals were identified with actinic keratosis, the most common type of precancerous skin lesion that affects 1.3 million people annually. Physicians also detected 165 individuals with squamous cell carcinoma, a fast growing form of skin cancer that affects 200,000 people each year, and 538 individuals with basal cell carcinoma, which affects more than 800,000 annually. Melanoma, the most serious form of skin cancer, was detected in 59 individuals.

According to the American Cancer Society, more than one million new cases of skin cancer will be diagnosed in the United States this year and one in five Americans will develop some form of skin cancer during their lifetime. Invasive melanoma is the sixth most common cancer in men and women and the second most common cancer in women aged 20-29 years old.

“We are extremely proud of how successful the Tour is, and are thankful to all the physicians who provided complimentary skin cancer screenings to thousands of individuals. Also, we raised considerable public awareness about the need to visit a dermatologist for early skin cancer detection,” stated Daniel Glassman, President and CEO of Bradley Pharmaceuticals. “Since more than one million people will be diagnosed with skin cancer this year, annual screening is an important part of a complete health regimen. As the summer begins, more individuals will engage in outdoor activities and be exposed to sunlight. We encourage everyone to visit their dermatologist and be screened this year.”

To learn more about The Skin Cancer Screening Tour and find a list of upcoming events, please visit http://www.skincancerscreeningtour.com, or the Bradley Pharmaceuticals website at: http://www.bradpharm.com.

Bradley Pharmaceuticals common stock is listed on the NYSE under BDY.

Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley’s success is based upon its core strengths in marketing and sales which enables the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley’s marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.

source : www.medicalnewstoday.com